• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Clinical trials roundup: Abiomed wins conditional FDA approval for Impella study on heart attack recovery

Clinical trials roundup: Abiomed wins conditional FDA approval for Impella study on heart attack recovery

December 4, 2010 By MassDevice staff

Clinical trials roundup

Here’s a roundup of recent clinical trial news:

  • Abiomed Receives Conditional FDA Approval for Study with Impella 2.5 in Reducing Heart Muscle Damage Following PCI in STEMI Patients
    Abiomed, Inc. (NSDQ:ABMD), a provider of heart support technologies, announced it has received conditional approval from the Food & Drug Administration to begin MINI-AMI, a prospective, randomized, controlled multi-site trial to assess the potential role of the Impella® 2.5 in reducing infarct size in patients with ST-elevation myocardial infarction (STEMI). The primary objective of this study is to evaluate whether the adjunctive use of the Impella 2.5 for 24 hours following primary percutaneous intervention (PCI) for STEMI has the potential to limit the infarction of at-risk myocardium compared to primary PCI with routine post-PCI care.
    Read more
  • Midterm results from a multicenter registry on the treatment of infrainguinal critical limb ischemia using a heparin-bonded ePTFE graft
    Over a 7-year period ending in 2008, 425 patients presenting with critical limb ischemia underwent infrainguinal revascularization using a heparin-bonded ePTFE graft in seven Italian vascular centers. The use of a heparin-bonded ePTFE graft provides good early and midterm results, with low rates of late amputations. Primary and secondary patency made this graft an excellent alternative to autologous saphenous vein when it is absent, unsuitable, or of poor quality.

    Read more

  • Inspire Medical Systems Announces FDA approval for Pivotal Clinical Trial
    Inspire Medical Systems, a developer of neuro-stimulation therapies for the treatment of obstructive sleep apnea (OSA), announced that the company has received approval from the Food and Drug Administration (FDA) to begin its STAR pivotal clinical trial.
    Read more
  • KineMed reports clinical data on novel method for identifying and verifying biomarker candidates in cerebral spinal fluid for Parkinson’s Disease to the Michael J. Fox Foundation
    KineMed Inc. presents data on the new use of cerebrospinal fluid biomarkers of microtubule-mediated neuronal transport for the monitoring of disease progression and the advancement of therapeutic interventions in Parkinson’s disease, a debilitating neurological condition with considerable unmet need for new treatments.
    Read more
  • New study shows DNA test highly accurate in predicting curve progression in scoliosis Patients
    A new study shows the SCOLISCORE™ AIS Prognostic Test, a DNA test to determine the likelihood of curve progression in children with mild adolescent idiopathic scoliosis (AIS), an abnormal curvature of the spine, is 99 percent accurate in predicting which children are least likely to progress to a severe curve (Cobb Angle of 40 degrees or more).
    Read more
  • California Stem Cell Inc. files IND to commence phase I clinical trial in spinal muscular atrophy
    California Stem Cell, Inc. and Families of Spinal Muscular Atrophy (FSMA) announced that CSC has filed an investigational new drug application with the US Food & Drug Administration for approval to commence a Phase I safety study on a jointly-developed stem cell-derived motor neuron transplantation therapy for Spinal Muscular Atrophy Type I.
    Read more
  • Micell Technologies enrolls first patient in DESSOLVE I first-in-human study of MiStent DES
    Micell Technologies, TM Inc. announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with Sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lEsions in the native coronary arteries), a first-in-human clinical trial of the company’s investigational MiStentTM Drug Eluting Coronary Stent System.
    Read more
  • Advanced Cell Technology files IND with FDA for first clinical trial using embryonic stem cells to treat dry AMD
    Advanced Cell Technology Inc. (OTC:ACTC) announced that it has filed an Investigational New Drug (IND) Application with the US Food & Drug Administration to initiate a Phase I/II multicenter study using human embryonic stem cell (hESC) derived retinal pigment epithelial (RPE) cells to treat patients with Dry Age-Related Macular Degeneration.
    Read more
  • Phase 2 clinical study demonstrates safety and efficacy of Vitala™ continence control device
    Vitala™ a novel, non-invasive continence control device, demonstrated safety and efficacy in providing up to 8 hours of temporary continence to people with an end colostomy, according to results of a study published in the journal Diseases of the Colon & Rectum.
    Read more
  • Acupuncture changes brain’s perception and processing of pain
    Using functional magnetic resonance imaging (fMRI), researchers have captured pictures of the brain while patients experienced a pain stimulus with and without acupuncture to determine acupuncture’s effect on how the brain processes pain. Results of the study, which the researchers say suggest the effectiveness of acupuncture, were presented at the annual meeting of the Radiological Society of North America (RSNA).
    Read more
  • AAOS fails to consider new research offering level 1 evidence in favor of vertebroplasty
    Results of a large-scale study, “Vertebroplasty vs. Conservative Treatment in Osteoporotic Vertebral Compression Fractures” (VERTOS II), provides Level 1 evidence that vertebroplasty helps relieve the pain caused by vertebral compression fractures at an acceptable cost. The study also helps define the type of patient for whom the procedure is most suitable and effective.
    Read more
  • Abnormal blood vessel function found in women with broken heart syndrome
    A team of Mayo Clinic researchers has found that patients with broken heart syndrome, also known as apical ballooning syndrome (ABS), have blood vessels that don’t react normally to stress. These results offer clues to the cause of this rare syndrome and may help with efforts to identify patients who are more vulnerable to mental stress so that appropriate therapies can be developed. The study is published online in the Journal of the American College of Cardiology.
    Read more
  • A less invasive method of determining the stage of non-small-cell lung cancer proves effective
    A study published in The Journal of the American Medical Association showed that patients may not need a surgical procedure to for doctors to learn the stage of their lung dancer.
    Read more
  • OrbusNeich’s Genous™ stent shows favorable outcomes for treatment of coronary artery bifurcation lesions compared to bare metal stents
    OrbusNeich’s Genous Stent shows favorable outcomes compared to bare metal stents (BMS) for the treatment of coronary artery bifurcation lesions, according to data published online in the journal Atherosclerosis.
    Read more

Filed Under: Business/Financial News, News Well Tagged With: Abiomed, Gift Bans

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy